Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience

被引:15
作者
Fattizzo, Bruno [1 ,2 ]
Levati, Giorgia Virginia [2 ]
Giannotta, Juri Alessandro [1 ]
Cassanello, Giulio [2 ]
Cro, Lilla Marcella [3 ]
Zaninoni, Anna [1 ]
Barbieri, Marzia [3 ]
Croci, Giorgio Alberto [4 ]
Revelli, Nicoletta [5 ]
Barcellini, Wilma [1 ]
机构
[1] Fdn IRCCS CaGranda Osped Maggiore Policlin, Hematol Unit, Milan, Italy
[2] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
[3] Fdn IRCCSCaGranda Osped Maggiore Policlin, Cytofluorimetry Serv, Cent Lab Unit, Milan, Italy
[4] Fdn IRCCS CaGranda Osped Maggiore Policlin, Pathol Unit, Milan, Italy
[5] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Transfus Med & Hematol, Immunohematol Reference Lab, Milan, Italy
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
low-risk myelodysplastic syndromes; autoimmunity; somatic mutations; hypoplastic myelodysplastic syndromes; bone marrow microenvironment; PROGNOSTIC SCORING SYSTEM; IMMUNOLOGICAL ABNORMALITIES; MDS; MUTATIONS; CLASSIFICATION; CYCLOSPORINE; ANTIBODIES; IMMUNE; SERUM;
D O I
10.3389/fonc.2022.795955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusion support. The contribution of molecular lesions and of autoimmune phenomena to pathogenesis and clinical course, including leukemic evolution, is a field of open investigation. We analyzed data from a cohort of 226 patients with LR-MDS followed at our center in the last 20 years, focusing on morphological, immunological (antiplatelets and anti-erythrocyte autoantibodies, anti-erythroblast antibodies), and molecular features. Hypoplastic bone marrow was found in 7% of the cases correlating with younger age, deeper cytopenia, lower dysplasia, and worse response to ESAs. A marker of autoimmunity was observed in 46% of the tested cases, who were younger, were less frequent dysplastic changes, and responded better to ESAs and steroids. Finally, 68% of the tested cases displayed at least one somatic mutation, most commonly SF3B1, TET2, ASXL1, and SRSF2, associated with older age, presence of neutropenia, and lower response to ESAs. Leukemic evolution (2.2%) was associated with presence of somatic mutations, and survival was favorably related to response to ESAs and transfusion independence. Overall, granular evaluation and re-evaluation are pivotal in LR-MDS patients to optimize clinical management.
引用
收藏
页数:11
相关论文
共 45 条
[1]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[2]   Anti-erythroblast autoimmunity in early myelodysplastic syndromes [J].
Barcellini, Wilma ;
Zaninoni, Anna ;
Imperiali, Francesca G. ;
Boschetti, Carla ;
Colombi, Mariangela ;
Iurlo, Alessandra ;
Zanella, Alberto .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :19-26
[3]   Autoimmune Complications in Hematologic Neoplasms [J].
Barcellini, Wilma ;
Giannotta, Juri Alessandro ;
Fattizzo, Bruno .
CANCERS, 2021, 13 (07)
[4]   Clinical Effect of Point Mutations in Myelodysplastic Syndromes [J].
Bejar, Rafael ;
Stevenson, Kristen ;
Abdel-Wahab, Omar ;
Galili, Naomi ;
Nilsson, Bjoern ;
Garcia-Manero, Guillermo ;
Kantarjian, Hagop ;
Raza, Azra ;
Levine, Ross L. ;
Neuberg, Donna ;
Ebert, Benjamin L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2496-2506
[5]   Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register [J].
Berggren, Daniel Moreno ;
Folkvaljon, Yasin ;
Engvall, Marie ;
Sundberg, Johan ;
Lambe, Mats ;
Antunovic, Petar ;
Garelius, Hege ;
Lorenz, Fryderyk ;
Nilsson, Lars ;
Rasmussen, Bengt ;
Lehmann, Soren ;
Hellstrom-Lindberg, Eva ;
Jadersten, Martin ;
Ejerblad, Elisabeth .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (05) :614-627
[6]   Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma [J].
Bernard, S. ;
Hachon, L. ;
Diasonama, J. F. ;
Madaoui, C. ;
Aguinaga, L. ;
Miekoutima, E. ;
Moatti, H. ;
Perrial, Emeline ;
Madelaine, I. ;
Brice, P. ;
Thieblemont, Catherine .
ANNALS OF HEMATOLOGY, 2021, 100 (04) :979-986
[7]   Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome [J].
Bono, Elisa ;
McLornan, Donal ;
Travaglino, Erica ;
Gandhi, Shreyans ;
Galli, Anna ;
Khan, Alesia Abigael ;
Kulasekararaj, Austin G. ;
Boveri, Emanuela ;
Raj, Kavita ;
Elena, Chiara ;
Ireland, Robin M. ;
Bianchessi, Antonio ;
Jiang, Jie ;
Todisco, Gabriele ;
Ferretti, Virginia Valeria ;
Cazzola, Mario ;
Marsh, Judith C. W. ;
Malcovati, Luca ;
Mufti, Ghulam J. .
LEUKEMIA, 2019, 33 (10) :2495-2505
[8]  
Brunner AM., 2021, BLOOD, V138, P244, DOI DOI 10.1182/BLOOD-2021-146039
[9]   Myelodysplastic Syndromes [J].
Cazzola, Mario .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1358-1374
[10]   Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies [J].
Chao, Mark P. ;
Takimoto, Chris H. ;
Feng, Dong Dong ;
McKenna, Kelly ;
Gip, Phung ;
Liu, Jie ;
Volkmer, Jens-Peter ;
Weissman, Irving L. ;
Majeti, Ravindra .
FRONTIERS IN ONCOLOGY, 2020, 9